Major US pharmaceutical companies are accelerating partnerships with Chinese biotech firms despite efforts to decouple from Beijing's biomedical sector. Bristol...
-
-
Recent Updates
- US Pharma Firms Forge Deals with Chinese Biotechs Amid Regulatory Pushback
- Troubles in China: Economic Slowdown Persists Amidst Industrial and Retail Blues
- Suspected China APT Behind VMware Exploitation: Cybersecurity Recap
- US Urges Countries to Choose Between Pax Silica and Beijing’s AI Framework
- Crosswinds and Market Indicators: A Week of Key Data and Earnings Reports
- Insilico Medicine Included in MSCI Global Small Cap Index, Recognized for Core Strengths in Capital Markets
- CATL Achieves Core Operation Carbon Neutrality, Launches Industry-Leading Carbon Neutrality Action
- United States Urges Countries to Choose Sides in Global AI Race Amid China’s Growing Influence
- China’s Self-Driving Advances in Europe: Momenta and Pony.ai Expand Reach
- CXMT’s Emergence as China’s Most Valuable Company Marks Shift in Tech Landscape
Blogroll